Hormone Investigational

Apelin

An endogenous peptide ligand for the APJ receptor with cardiovascular and metabolic research relevance.

Endogenous PeptideCardiovascularMetabolicInvestigational

Also appears in: Other

Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Category
Hormone

Primary lane: Hormone. Also surfaces under Other for browsing and discovery.

Aliases
0

No major aliases are tracked for this profile yet.

Signal depth
Medium

No FDA label signal · 65 trials · 2965 PubMed results

Promising
Research evidence

Apelin has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Apelin has 29 name-matched clinical trials (highest phase: Phase 3) and 2967 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.

Human data
Phase 3
Trial quality
Randomized
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Top-tier journals
PHASE2/PHASE3 · Randomized Effects of Zinc Supplementation on Anthropometric Factors, Apelin and Inflammatory Markers in Obese Individuals PHASE2 · Randomized A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE1 · Randomized Effect of Apelin on Insulin Sensitivity: Proof of Concept in Healthy Volunteers Endocrinology · 889 citations Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity Journal of Neurochemistry · 677 citations Characterization of Apelin, the Ligand for the APJ Receptor Regulatory Peptides · 644 citations The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What apelin is

Apelin is an endogenous peptide ligand of the APJ receptor and has been studied in cardiovascular, fluid-balance, and metabolic contexts.

Why it matters

It helps strengthen the library’s scientific credibility by covering important physiology peptides that are real and relevant even when they are not gray-market hype names.

Regulatory context

Apelin is not FDA approved as a standard peptide therapy in the United States.

Practical reading note

Apelin is the kind of peptide that makes the library smarter, not just bigger.